Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 4Neoplasms 3Breast Neoplasms 3Recurrence 2Hypersensitivity 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoadjuvant Therapy 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 158Paclitaxel 152Bevacizumab 85Gemcitabine 48liposomal doxorubicin 47Taxes 47Topotecan 41Cisplatin 34pembrolizumab 33Cyclophosphamide 28olaparib 25Immunoglobulin G 24Disulfides 24Specimen Handling 20Docetaxel 20Drug Therapy 19Magnetic Resonance Spectroscopy 17niraparib 16Doxorubicin 16Biopsy 15mirvetuximab soravtansine 14Hyperthermic Intraperitoneal Chemotherapy 13rucaparib 12Nivolumab 12Cytoreduction Surgical Procedures 10Albumin-Bound Paclitaxel 10veliparib 9Platinum 9Chemotherapy, Adjuvant 9130-nm albumin-bound paclitaxel 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Fallopian Tube Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡